Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · SANUWAVE Health, Inc. (SNWV)

Sanuwave withdraws 2026 guidance as Q2 revenue falls 3% and it posts a $0.7 million net loss

Negative Impact 4 of 5 guidance Written later

Sanuwave reported second-quarter 2026 revenue of $9.7 million, down 3% from $10.1 million a year earlier, and a net loss of $0.7 million compared with net income of $0.6 million in the prior-year quarter. The company withdrew its fiscal 2026 guidance, which it says should no longer be relied upon, citing Medicare reimbursement developments and will not issue new guidance until it has more clarity, expected after CMS publishes its final rule in the fourth quarter of 2026.

Key points

  • Q2 2026 revenue was $9.7 million, down 3% from $10.1 million in Q2 2025; gross margin was 76.2% versus 78.1%
  • Net loss was $0.7 million, or $(0.08) per share, versus net income of $0.6 million in Q2 2025
  • Adjusted EBITDA was $1.2 million versus $3.2 million a year earlier; 82 Ultramist systems were sold versus 116 in Q2 2025
  • Fiscal 2026 guidance withdrawn; no new guidance until CMS publishes its final rule, anticipated in Q4 2026

The filing

CompanySANUWAVE Health, Inc. (SNWV)
Form8-K, current report
Filed with the SECAug 6, 2026, 5:07 PM ET
Accession number0001628280-26-054459

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.